Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PIK3CA wild-type PTEN loss |
Therapy | Torkinib + U0126 |
Indication/Tumor Type | breast cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA wild-type PTEN loss | breast cancer | sensitive | Torkinib + U0126 | Preclinical - Cell culture | Actionable | In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of Torkinib (PP242) and U0126 in culture (PMID: 21358673). | 21358673 |
PubMed Id | Reference Title | Details |
---|---|---|
(21358673) | PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. | Full reference... |